LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset - HMS LINCS Database

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 30 of 66
Next
>>
>
726 to 750 of 1647 records
per page:

Small Molecule	barcode	cell_count	frac_dead	corpse_count	cell_count_dead	row	column	agent	concentration	role	timepoint	replicate	cell_line	dead_count	fraction_dead	cell_count__time0	dead_count__time0	cell_count__ctrl	dead_count__ctrl	fraction_dead__ctrl	increase_fraction_dead	GRvalue
Etoposide	180619_MC_11	14663	0.0137	42	160	12	18	Etoposide	0.003326667	treatment	72	2	MCF10A-GM_6	202	0.0136	635.9	71.1	15071	356.7	0.0231	-0.00949	0.9880
Etoposide	180619_MC_12	13759	0.0295	149	261	11	4	Etoposide	0.003326667	treatment	72	2	MCF10A-GM_7	410	0.0289	635.9	71.1	15071	356.7	0.0231	0.00586	0.9605
Etoposide	180619_MC_12	13877	0.0327	172	287	11	7	Etoposide	0.003326667	treatment	72	2	MCF10A-GM_8	459	0.0320	635.9	71.1	15071	356.7	0.0231	0.00894	0.9642
Etoposide	180619_MC_12	14937	0.0222	95	239	14	8	Etoposide	0.003326667	treatment	72	2	MCF10A-GM_9	334	0.0219	635.9	71.1	15071	356.7	0.0231	-0.00120	0.9961
Etoposide	180619_MC_10	14567	0.0236	79	267	9	5	Etoposide	0.00998	treatment	72	2	MCF10A-GM_1	346	0.0232	635.9	71.1	15071	356.7	0.0231	0.00013	0.9852
Etoposide	180619_MC_10	13777	0.0216	90	210	9	17	Etoposide	0.00998	treatment	72	2	MCF10A-GM_2	300	0.0213	635.9	71.1	15071	356.7	0.0231	-0.00176	0.9611
Etoposide	180619_MC_10	13577	0.0166	40	186	12	20	Etoposide	0.00998	treatment	72	2	MCF10A-GM_3	226	0.0164	635.9	71.1	15071	356.7	0.0231	-0.00670	0.9548
Etoposide	180619_MC_11	14114	0.0185	63	199	4	3	Etoposide	0.00998	treatment	72	2	MCF10A-GM_4	262	0.0182	635.9	71.1	15071	356.7	0.0231	-0.00485	0.9715
Etoposide	180619_MC_11	14737	0.0207	44	262	6	14	Etoposide	0.00998	treatment	72	2	MCF10A-GM_5	306	0.0203	635.9	71.1	15071	356.7	0.0231	-0.00273	0.9902
Etoposide	180619_MC_11	14888	0.0220	66	263	8	14	Etoposide	0.00998	treatment	72	2	MCF10A-GM_6	329	0.0216	635.9	71.1	15071	356.7	0.0231	-0.00145	0.9947
Etoposide	180619_MC_12	13699	0.0302	164	254	7	6	Etoposide	0.00998	treatment	72	2	MCF10A-GM_7	418	0.0296	635.9	71.1	15071	356.7	0.0231	0.00654	0.9586
Etoposide	180619_MC_12	14612	0.0243	105	253	8	6	Etoposide	0.00998	treatment	72	2	MCF10A-GM_8	358	0.0239	635.9	71.1	15071	356.7	0.0231	0.00084	0.9865
Etoposide	180619_MC_12	15260	0.0220	76	262	12	17	Etoposide	0.00998	treatment	72	2	MCF10A-GM_9	338	0.0217	635.9	71.1	15071	356.7	0.0231	-0.00140	1.0055
Etoposide	180619_MC_10	12190	0.0218	70	197	9	12	Etoposide	0.033266667	treatment	72	2	MCF10A-GM_1	267	0.0214	635.9	71.1	15071	356.7	0.0231	-0.00164	0.9092
Etoposide	180619_MC_10	11770	0.0190	63	162	11	21	Etoposide	0.033266667	treatment	72	2	MCF10A-GM_2	225	0.0188	635.9	71.1	15071	356.7	0.0231	-0.00432	0.8946
Etoposide	180619_MC_10	10930	0.0156	38	133	14	9	Etoposide	0.033266667	treatment	72	2	MCF10A-GM_3	171	0.0154	635.9	71.1	15071	356.7	0.0231	-0.00767	0.8641
Etoposide	180619_MC_11	11229	0.0229	54	204	5	9	Etoposide	0.033266667	treatment	72	2	MCF10A-GM_4	258	0.0225	635.9	71.1	15071	356.7	0.0231	-0.00061	0.8752
Etoposide	180619_MC_11	11814	0.0205	63	181	12	7	Etoposide	0.033266667	treatment	72	2	MCF10A-GM_5	244	0.0202	635.9	71.1	15071	356.7	0.0231	-0.00284	0.8962
Etoposide	180619_MC_11	12203	0.0186	67	161	12	11	Etoposide	0.033266667	treatment	72	2	MCF10A-GM_6	228	0.0183	635.9	71.1	15071	356.7	0.0231	-0.00473	0.9097
Etoposide	180619_MC_12	12993	0.0279	130	236	3	12	Etoposide	0.033266667	treatment	72	2	MCF10A-GM_7	366	0.0274	635.9	71.1	15071	356.7	0.0231	0.00432	0.9361
Etoposide	180619_MC_12	13441	0.0221	94	205	4	10	Etoposide	0.033266667	treatment	72	2	MCF10A-GM_8	299	0.0218	635.9	71.1	15071	356.7	0.0231	-0.00131	0.9505
Etoposide	180619_MC_12	14317	0.0255	143	226	9	14	Etoposide	0.033266667	treatment	72	2	MCF10A-GM_9	369	0.0251	635.9	71.1	15071	356.7	0.0231	0.00205	0.9776
Etoposide	180619_MC_10	7535	0.0207	83	75	7	4	Etoposide	0.099799999	treatment	72	2	MCF10A-GM_1	158	0.0205	635.9	71.1	15071	356.7	0.0231	-0.00254	0.7183
Etoposide	180619_MC_10	7822	0.0224	93	84	9	13	Etoposide	0.099799999	treatment	72	2	MCF10A-GM_2	177	0.0221	635.9	71.1	15071	356.7	0.0231	-0.00095	0.7325
Etoposide	180619_MC_10	6868	0.0185	55	73	14	17	Etoposide	0.099799999	treatment	72	2	MCF10A-GM_3	128	0.0183	635.9	71.1	15071	356.7	0.0231	-0.00478	0.6838

|<
<<
Previous
Page 30 of 66
Next
>>
>
726 to 750 of 1647 records
per page:

HMS LINCS Project

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)